Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders
Authors:
Open Access
- 21 July 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1209749
Abstract
Myelin oligodendrocyte glycoprotein (MOG) is expressed on the outermost layer of the myelin sheath in the central nervous system. Recently, the clinical concept of MOG antibody-associated disease (MOGAD) was established based on the results of human MOG-transfected cell-based assays which can detect conformation-sensitive antibodies against MOG. In this review, we summarized the pathological findings of MOGAD and discussed the issues that remain unresolved. MOGAD pathology is principally inflammatory demyelination without astrocyte destruction, characterized by perivenous demyelination previously reported in acute disseminated encephalomyelitis and by its fusion pattern localized in both the white and gray matter, but not by radially expanding confluent demyelination typically seen in multiple sclerosis (MS). Some of demyelinating lesions in MOGAD show severe loss of MOG staining compared with those of other myelin proteins, suggesting a MOG-targeted pathology in the disease. Perivascular cuffings mainly consist of macrophages and T cells with CD4-dominancy, which is also different from CD8+ T-cell-dominant inflammation in MS. Compared to aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorders (NMOSD), perivenous complement deposition is less common, but can be seen on myelinated fibers and on myelin degradation products within macrophages, resembling MS Pattern II pathology. Thus, the pathogenetic contribution of complements in MOGAD is still debatable. Together, these pathological features in MOGAD are clearly different from those of MS and AQP4 antibody-positive NMOSD, suggesting that MOGAD is an independent autoimmune demyelinating disease entity. Further research is needed to clarify the exact pathomechanisms of demyelination and how the pathophysiology relates to the clinical phenotype and symptoms leading to disability in MOGAD patients.Keywords
This publication has 90 references indexed in Scilit:
- Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal ArraysJournal of Biological Chemistry, 2012
- Pathology of Demyelinating DiseasesAnnual Review of Pathology: Mechanisms of Disease, 2012
- Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disordersJournal of Neuroinflammation, 2011
- Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosisBrain, 2010
- Multiple Sclerosis and the Spectrum of CNS Inflammatory Demyelinating DiseasesSeminars in Neurology, 2008
- Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport1Journal of Neurochemistry, 2007
- Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non‐human primatesJournal of Neurochemistry, 2006
- Immunopathology of secondary‐progressive multiple sclerosisAnnals of Neurology, 2001
- Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the diseaseJournal of Autoimmunity, 1989
- Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesionsActa Neuropathologica, 1988